HYPR Hyperfine, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1833769 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.0%
TTM net income YoY25.6%
TTM EPS YoY44.2%
Revenue 3-yr CAGR25.0%
Net income 3-yr CAGR—
Margins
Gross margin52.6%
Operating margin-167.6%
Net margin-156.4%
FCF margin-146.5%
EBITDA margin-162.0%
Returns
ROE-101.7%
ROA-60.0%
ROIC (approx.)-402.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets45.1%
Debt / equity0.42x
Current ratio5.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.96M | $3.90M | $3.90M | $5.29M | $3.44M | $2.70M | $2.14M | $2.32M |
| Cost of revenue | $2.58M | $1.92M | $1.92M | $2.60M | $1.59M | $1.37M | $1.25M | $1.50M |
| Gross profit | $3.38M | $1.98M | $1.98M | $2.69M | $1.85M | $1.33M | $883,000 | $826,000 |
| R&D expense | $3.91M | $3.87M | $3.85M | $3.83M | $4.05M | $4.54M | $5.04M | $5.11M |
| SG&A expense | $4.05M | $3.91M | $4.13M | $4.03M | $4.15M | $3.86M | $4.21M | $4.13M |
| Operating income | -$7.26M | -$8.47M | -$8.56M | -$7.67M | -$8.92M | -$9.60M | -$10.90M | -$10.77M |
| Interest expense | $549,000 | $533,000 | $83,000 | — | $0 | $0 | $0 | — |
| Pretax income | -$5.98M | -$9.30M | -$8.62M | -$5.91M | -$11.02M | -$9.22M | -$9.42M | -$10.39M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.98M | -$9.30M | -$8.62M | -$5.91M | -$11.02M | -$9.22M | -$9.42M | -$10.39M |
| EBITDA | -$7.01M | -$8.21M | -$8.28M | -$7.39M | -$8.62M | -$9.31M | -$10.67M | -$10.53M |
| EPS (basic) | -0.06 | -0.09 | -0.09 | — | -0.14 | -0.12 | -0.12 | — |
| EPS (diluted) | -0.06 | -0.09 | -0.09 | — | -0.14 | -0.12 | -0.12 | — |
| Weighted avg. shares (diluted) | 106.11M | 99.80M | 97.70M | — | 79.03M | 78.08M | 75.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $37.87M | $43.46M | $40.78M | $35.09M | $21.56M | $25.42M | $33.09M | $37.67M |
| Receivables | $5.18M | $4.22M | $3.79M | $5.25M | $4.89M | $5.06M | $5.33M | $5.96M |
| Inventory | $6.38M | $6.79M | $6.33M | $7.09M | $5.84M | $4.88M | $4.64M | $5.83M |
| Current assets | $53.75M | $59.24M | $56.03M | $50.91M | $36.90M | $40.10M | $48.40M | $53.71M |
| PP&E, net | $2.09M | $2.26M | $2.50M | $2.55M | $2.75M | $3.12M | $3.09M | $3.12M |
| Total assets | $57.79M | $63.00M | $60.34M | $55.26M | $41.51M | $45.23M | $53.38M | $58.90M |
| Current liabilities | $10.53M | $9.63M | $10.15M | $11.73M | $10.17M | $7.99M | $7.98M | $8.73M |
| Short-term debt | $0 | $0 | $0 | — | — | — | — | — |
| Long-term debt | $13.35M | $13.23M | $13.12M | $0 | — | — | — | — |
| Total debt | $13.35M | $13.23M | $13.12M | $0 | — | — | — | — |
| Total liabilities | $26.05M | $26.24M | $25.98M | $14.26M | $14.64M | $10.11M | $10.26M | $9.86M |
| Shareholders' equity | $31.74M | $36.76M | $34.36M | $41.01M | $26.87M | $35.13M | $43.11M | $49.04M |
| Net debt | -$24.52M | -$30.22M | -$27.66M | -$35.09M | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.08M | -$7.27M | -$9.01M | -$5.21M | -$5.58M | -$7.91M | -$9.25M | -$8.36M |
| Capital expenditure | $21,000 | $30,000 | $242,000 | $63,000 | $130,000 | $520,000 | $472,000 | $8,000 |
| Free cash flow | -$6.10M | -$7.30M | -$9.25M | -$5.27M | -$5.71M | -$8.43M | -$9.72M | -$8.37M |
| Investing cash flow | -$21,000 | -$30,000 | -$242,000 | -$63,000 | -$130,000 | -$520,000 | -$472,000 | -$8,000 |
| Financing cash flow | -$10,000 | $10.78M | $14.49M | $19.28M | $2.16M | $474,000 | $5.58M | $54,000 |
| Depreciation & amortization | $251,000 | $264,000 | $274,000 | $281,000 | $297,000 | $283,000 | $229,000 | $234,000 |
| Stock-based compensation | $962,000 | $903,000 | $647,000 | $692,000 | $617,000 | $547,000 | $945,000 | $1.05M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.